File this under “one step forward, two steps back.”
Just one week after Pfizer hoped to resume full production at a manufacturing plant with long-standing quality control problems, the drug maker has had to hit the pause button on some activities due to “additional maintenance” that needs to be performed, according to a company spokesman.
The setback is only the latest blow to Pfizer as it struggles to overhaul its troubled plant in McPherson, Kan., which has experienced a series of debilitating issues that have caused numerous product shortages and prompted ongoing concerns from regulators.
About the Author Reprints
